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Articles
Provision of medical supply kits to improve quality of 
antenatal care in Mozambique: a stepped-wedge cluster 
randomised trial
Ana Pilar Betrán, Eduardo Bergel, Sally Griffin, Armando Melo, My Huong Nguyen, Alicia Carbonell, Santos Mondlane, Mario Merialdi, 
Marleen Temmerman, A Metin Gülmezoglu, for the WHO Antenatal Care Trial in Mozambique Research Group* 
Summary
Background High levels of maternal and newborn mortality and morbidity remain a daunting reality in many low-
income countries. Several interventions delivered during antenatal care have been shown to improve maternal and 
newborn outcomes, but stockouts of medical supplies at point of care can prevent implementation of these services. 
We aimed to evaluate whether a supply chain strategy based on the provision of kits could improve quality of care.
Methods We did a pragmatic, stepped-wedge, cluster-randomised controlled trial at ten antenatal care clinics in 
Mozambique. Clinics were eligible if they were not already implementing the proposed antenatal care package; 
they served at least 200 new pregnant women per year; they had Maternal and Child Health (MCH) nurses; and 
they were willing to participate. All women attending antenatal care visits at the participating clinics were included 
in the trial. Participating clinics were randomly assigned to shift from control to intervention on prespeciﬁed start 
dates. The intervention involved four components (kits with medical supplies, a cupboard to store these supplies, a 
tracking sheet to monitor stocks, and a one-day training session). The primary outcomes were the proportion of 
women screened for anaemia and proteinuria, and the proportion of women who received mebendazole in the ﬁrst 
antenatal care visit. The intervention was delivered under routine care conditions, and analyses were done according 
to the intention-to-treat principle. This trial is registered with the Pan African Clinical Trial Registry, number 
PACTR201306000550192.
Findings Between March, 2014, and January, 2016, 218 277 antenatal care visits were registered, with 68 598 ﬁrst and 
149 679 follow-up visits. We found signiﬁcant improvements in all three primary outcomes. In ﬁrst visits, 5519 (14·6%) 
of 37 826 women were screened for anaemia in the control period, compared with 30 057 (97·7%) of 30 772 in the 
intervention period (adjusted odds ratio 832·40; 99% CI 666·81–1039·11; p<0·0001); 3739 (9·9%) of 37 826 women 
were screened for proteinuria in the control period, compared with 29 874 (97·1%) of 30 772 in the intervention 
period (1875·18; 1447·56–2429·11; p<0·0001); and 17 926 (51·4%) of 34 842 received mebendazole in the control 
period, compared with 24 960 (88·2%) of 28 294 in the intervention period (1·88; 1·70–2·09; p<0·0001). The eﬀect 
was immediate and sustained over time, with negligible heterogeneity between sites.
Interpretation A supply chain strategy that resolves stockouts at point of care can result in a vast improvement in 
quality during antenatal care visits, when compared with the routine national process for procurement and 
distribution of supplies.
Funding Government of Flanders and the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of 
Research, Development and Research Training in Human Reproduction.
Copyright © 2017 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. In any use of this Article, there should be no suggestion that WHO endorses any 
speciﬁc organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved 
along with the Article’s original URL.
Introduction
Although progress in reduction of maternal mortality in 
the past two decades has been systematically documented, 
it remains a daunting challenge, particularly in low-resource 
countries.1 If eﬀectively implemented, antenatal care can be 
an important contributor to the reduction of maternal 
mortality.2–4 Additionally, in many poor settings, antenatal 
care constitutes one of the few times women might seek 
contact with the health system during their reproductive 
life.4,5 For this reason, antenatal care represents a unique 
opportunity to inform, educate, and reach women with a 
number of interventions that can be vital for maternal and 
perinatal health.
In low-resource settings, multiple factors hinder the 
delivery of evidence-based practices for antenatal care.6–10 
One of the most basic and limiting bottlenecks revolves 
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around procurement and supply chain deﬁciencies that 
result in stockouts of key supplies at point of care.11 It is 
not enough to provide resources for medical supplies; 
these supplies have to be in the right place at the 
right time, consistently and reliably.11,12 Additionally, 
organisation of services is often suboptimal. For any 
antenatal care visit, the required set of health interventions 
is often delivered at several physical locations and requires 
multiple appointments, resulting in long waiting times 
and several visits to the facility.10
With a maternal mortality ratio of 489 maternal deaths 
per 100 000 livebirths in 2015, only 54% of births attended 
by a skilled birth attendant, and 51% of pregnant women 
receiving four or more antenatal care visits,1,13 Mozambique 
needs to develop and prioritise strategies to increase contact 
of pregnant women with the health system and to improve 
the quality and integration of antenatal care services. To 
explore deﬁciencies and potential solutions for improving 
antenatal care in Mozambique, WHO and the Mozambican 
Ministry of Health launched a two-pronged study in 2010. 
The formative research component of the study assessed 
factors aﬀecting the implementation of evidence-based 
antenatal care services.8,14 The ﬁndings of this study were 
then used to inform the development of an intervention to 
improve delivery of antenatal care, to be assessed through a 
subsequent randomised controlled trial.14
The methods and results of the formative research have 
been published elsewhere.8,14 This research identiﬁed 
deﬁcient infrastructure and poor functioning of the 
supply chain system—resulting in absence or scarcity of 
supplies—as major barriers to the delivery of antenatal 
care services, with a strong recommendation to strengthen 
supply chain functionality through the introduction of a kit 
system for supplying essential antenatal care commodities 
to health providers.8
We compared a supply chain strategy based on the 
provision of medical supply kits with the conventional 
procurement and distribution procedures used by the 
Ministry of Health in Mozambique, with respect to the 
delivery of practices for the detection, treatment, and 
prevention of major maternal and perinatal health-related 
conditions.
Methods
Study design
We did a pragmatic, facility-based, cluster randomised 
controlled trial with a stepped-wedge design in which 
participating antenatal care clinics were randomly assigned 
to shift from control to the intervention on prespeciﬁed 
dates. After 3 months of baseline data collection in all 
clinics, the intervention was rolled out sequentially to a 
new clinic every 2 months (length of the step). The trial 
Research in context 
Evidence before the study
Maternal and newborn mortality and morbidity remain 
unacceptably high in many low-resource settings. A substantial 
proportion of these adverse outcomes are preventable as several 
interventions have been shown to be effective and supported by 
high-quality evidence. This issue is particularly relevant during 
the antenatal period, since in many low-resource settings 
antenatal care visits represent the only opportunity for 
providing pregnant women with health-care services. However, 
stockouts of medical supplies at the point of care often prevent 
implementation of these services. The distribution of supply kits 
targeted at women, providers, or health facilities has been 
suggested as a strategy to increase the adoption of evidence-
based practices. However, the bulk of the evidence on the 
effectiveness of these kits derives from observational studies 
and has focused mainly on clean childbirth and reducing the 
incidence of infection and its complications, particularly in 
settings where women give birth at home. Despite the 
important role of antenatal care and the potential value of 
supply kits, to the best of our knowledge the delivery of supply 
kits at point of care to improve the quality of antenatal care 
visits has not been formally tested. The design of this trial was 
therefore based on the results of formative research that aimed 
to understand the barriers that hinder health practitioners’ 
ability or willingness to implement evidence-based antenatal 
care practices and on a national needs assessment of maternal 
and neonatal health. 
Added value of the study
The results of our stepped-wedge, cluster-randomised controlled 
trial show that the provision, at point of care, of supplies for 
evidence-based practices packaged in kits resulted in a vast 
improvement in the quality of antenatal care compared with the 
routine system for procurement and distribution of supplies 
used by the Ministry of Health of Mozambique. The effect was 
found to be immediate and sustained over time, with negligible 
heterogeneity between sites. The intervention improved care for 
the main drivers of maternal and infant morbidity and mortality, 
including hypertensive disorders of pregnancy, anaemia, and 
maternal infections. The combination of a robust design, large 
sample size, and large effect size provides a strong level of 
evidence to support the effectiveness of the intervention, since 
bias or random error are unlikely to explain these findings. This 
was a pragmatic trial designed from the ground up to inform 
policy makers. The study population included all women 
attending antenatal care visits and the intervention was 
delivered by available health-care workers under routine care 
conditions by use of the government antenatal care registration 
logbooks as a source of data.
Implications of all the available evidence
Policy makers should consider the use of supply kits to 
efficiently provide medical supplies at the right time, 
consistently, and reliably in settings where supply chain 
deficiencies and stockouts are major barriers to health care.
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lasted 23 months, including the 3 months of baseline data 
collection. The methods of the study are described in detail 
in the study protocol.14
Participants
Clusters were antenatal care clinics in health facilities 
selected purposely by the Ministry of Health according to 
its programmatic activities and priorities and with 
geographical representation of the three regions of 
Mozambique (north, centre, and south). Antenatal care 
clinics were eligible if they were not already implemen-
ting the proposed antenatal care package; they served at 
least 200 new pregnant women per year; they had 
Maternal and Child Health (MCH) nurses; and they were 
willing to participate. All women attending antenatal care 
visits at the participating clinics were included in the 
trial. The ten participating clinics have been described in 
the study protocol14 and are listed in the appendix. All 
clinics were Ministry of Health facilities and provided 
antenatal care free of charge under the public health 
system in which patients do not pay for maternal and 
child health care. All clinics provided the same standard 
of care in accordance with national Ministry of Health 
guidelines for antenatal care at health centre level. Two of 
the clinics (3-Songo and 5-Matola) received some addi-
tional resources from non-governmental partners.
Randomisation
Clinics were assigned to one of ten start dates by the 
study statistician via a computer-generated list of random 
numbers. Concealment of the intervention start date was 
not possible for logistic reasons, because of the involve-
ment of the Ministry of Health in the preparatory 
activities required to launch the intervention at each 
clinic.
Procedures
The intervention was multifaceted with four components 
described in the panel, which pertain to the cluster level: 
antenatal care kits (boxes containing supplies necessary 
to carry out a speciﬁc number of antenatal care visits); a 
cupboard to organise and store the supplies locked in the 
antenatal care room; a tracking sheet to monitor the kits’ 
stock levels; and a training session for the health-care 
providers at the beginning of the intervention.
The kits were designed by two experts in procurement 
and supply chain management on the basis of the 
evidence-based antenatal care interventions in the 
national guidelines (see the appendix for the list of 
interventions). Because of the importance of the ﬁrst 
antenatal care visit, the trial diﬀerentiated between ﬁrst 
and follow-up antenatal care visits (visits other than the 
ﬁrst). We designed four types of kits: Kit A contained 
supplies necessary to carry out 100 ﬁrst antenatal care 
visits; Kit B contained supplies necessary to carry out 
200 follow-up antenatal care visits; Kit C contained urine 
collection containers; and Kit D contained long-lasting 
impregnated bednets. For this trial, Kit A and Kit B were 
procured in the Netherlands and imported as ready-made 
boxes in accordance with national regulatory importing 
procedures. Kit C was purchased in Mozambique, and 
Kit D and antiretroviral drugs were provided through 
the Ministry of Health. The International Centre 
for Reproductive Health in Mozambique, the local 
implementing partner, was responsible for importation, 
storage, and distribution of the kits. Automatic 
sphygmomanometers with rechargeable batteries were 
part of the intervention but were not packed inside the 
kits because they were a one-time delivery. The full list of 
the products contained in Kits A and B, and photos of the 
kits, can be found in the appendix.
Data collection started in March, 2014, in all antenatal 
care clinics. The ﬁrst clinic entered the intervention in 
June, 2014, and the last in December, 2015. The dates of 
the launches of the intervention in each facility are 
shown in the appendix. Before the day of the launch, the 
local coordination team would be deployed to the clinic 
for preparation of the intervention. The kits were 
received, stored, and organised, the cupboard for storage 
was set up, and the antenatal care room or rooms were 
rearranged to accommodate changes in patient ﬂow 
required by the introduction of the intervention. The 
training session was carried out with attendance of all 
MCH nurses involved in antenatal care services at the 
Panel: Components of the intervention 
Component 1: antenatal care kits containing the necessary 
medicines, laboratory supplies, materials, and equipment
Four different kits were designed. Each health facility was 
provided with the antenatal care kits, which include the 
commodities required for first and follow-up antenatal care 
visits in accordance with Ministry of Health guidelines.
Component 2: cupboard
A cupboard for storage of the kits was provided in the room 
where the antenatal care visits took place, which allowed 
the nurses to have easy and quick access to all necessary 
materials during the antenatal care visit, and ensured 
secure storage of items.
Component 3: tracking sheet
A tracking sheet was introduced to monitor use of kits and 
stock levels to avoid stockouts. 
Component 4: training session
At the start of the intervention in each site, a refresher course 
on the essential interventions for antenatal care was held 
with all the Maternal and Child Health (MCH) nurses in the 
health facilities involved in delivering antenatal care, as well 
as the pharmacist and laboratory technician. These nurses 
were also trained in how to use the contents of the kit, such 
as the proteinuria test and blood pressure measurement, and 
in procedures to ensure continuous supply of the medicines 
and materials needed.
See Online for appendix
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clinic, as well as laboratory and pharmacy technicians. 
The content of the training is outlined in the panel. On 
the day of the launch, the nurses would start by 
addressing the awaiting pregnant women to explain the 
new system of kits and their contents, the antenatal care 
practices they were going to receive, the importance 
of these practices, and the advantages expected. This 
process was implemented ten times—before the launch 
of the intervention in each facility.
An oﬃcial from the Ministry of Health was actively 
involved in every step of the trial, including the launches 
and the monitoring visits. Nurses were supervised by 
the Ministry of Health in the context of their routine 
monitoring activities.
During the control period, each clinic provided 
antenatal care according to standard practice and 
functioned under the regular procurement system. The 
components of the antenatal care visits were the same in 
both groups, as per national guidelines (appendix). The 
kits contained, among other items, rapid tests for HIV, 
syphilis, haemoglobin, and proteinuria. Rapid tests for 
HIV and syphilis were already a routine part of antenatal 
care services before the intervention, whereas proteinuria 
and haemoglobin tests were only done at the laboratory.
Outcomes
Ten practices for women attending the ﬁrst antenatal care 
visit were initially targeted by the intervention and included 
in the protocol as primary outcome candidates.14 The 
protocol prespeciﬁed that three among those ten practices 
would be selected as primary outcomes, on the basis of 
the analysis of outcome delivery rates with data collected 
before the imple mentation of the intervention (ie, in 
step 1). This analysis was done during step 2 and the 
results are presented in the appendix. From the initial list 
of outcomes, iron/folic acid supplementation and tetanus 
toxoid administration were excluded before the analysis 
was done because the information required to compute 
these variables was not recorded in the antenatal care 
logbook. Screening for hypertensive disorders was split 
into its two elements: screening for high blood pressure 
and screening for proteinuria. These changes led to the 
ﬁnal list of nine outcomes that were evaluated for the ﬁrst 
antenatal care visits. The full list of outcomes and 
deﬁnitions is provided in the appendix. Among these nine 
practices, the three with the lowest delivery rate during 
step 1 were selected as primary outcomes: screening for 
proteinuria, screening for anaemia, and treatment of 
parasitic worms with mebendazole. The other six practices 
(screening for high blood pressure, preventive treatment 
for malaria, screening for HIV, treatment for HIV, 
screening for syphilis, and treatment for syphilis) were 
selected as secondary outcomes.
Secondary outcomes also included delivery of antenatal 
care practices in follow-up visits. These practices are 
described in the appendix. A composite outcome was 
also prespeciﬁed in the protocol.
All outcomes were measured with routine data 
extracted from the antenatal care logbook. Antenatal care 
nurses are required to register all antenatal care visits 
and practices delivered in each visit in standardised 
logbooks provided by the Ministry of Health (appendix). 
Although the Ministry of Health compiles data from 
monthly summaries generated by the nurses on the basis 
of the data in the logbooks, no system is in place for 
systematic digital storage of this information. Women do 
not have clinical records, and the logbook was the only 
source document for the trial. Data management 
procedures were developed and implemented in all ten 
participating antenatal care clinics with the purpose of 
transferring data in the logbook to the data management 
centre. Nurses were trained in how to complete the 
logbooks correctly by use of the coding system. Research 
assistants hired for the trial regularly reviewed the 
logbooks in each antenatal care clinic, took digital photos 
of each page of the logbook, and sent them to the data 
management centre in Maputo. We originally intended 
to link ﬁrst and follow-up antenatal care visits for each 
woman by assigning a unique study participant ID at 
enrolment; however, implementation of such a system 
was challenging in practice and it is only available for a 
subset of the data. Data management and quality control 
procedures have been described in the protocol14 and are 
summarised in the appendix. These procedures included 
several data quality audits and monitoring activities.
Statistical analysis
The Ministry of Health provided the number of antenatal 
care visits in each selected clinic for 2011, which was used 
to calculate the sample size, as reported in the study 
protocol.14 We assumed, conservatively, a baseline fre-
quency of 30% for each selected health practice, and an 
increase to 60% with implementation of the intervention. 
For a 0·05 alpha level, 80% power, and an intra-cluster 
correlation coeﬃcient of 0·05, six clusters were needed. 
To protect against pre-randomisation exclusions and 
dropouts, we decided to include ten clusters (antenatal 
care clinics). All sites completed the study and it is 
therefore overpowered for these initial assumptions.
Analyses were done according to the intention-to-treat 
principle.15 Because we prespeciﬁed three primary 
outcomes, the level of signiﬁcance was adjusted for 
multiple comparisons and set to 0·016 rather than 0·05. 
For dichotomous outcomes, a multilevel logistic regression 
was used to estimate odds ratios [OR] and 99% CI for 
exposure to the intervention across datapoints during the 
intervention period compared with the pre-intervention 
period. For the composite outcome score, mean diﬀerences 
and 99% CI were computed by use of multilevel linear 
regression.15 The clinic was entered in these models as a 
random eﬀect. Eﬀect sizes were adjusted for time trends 
by including time in the model as a ﬁxed eﬀect.
This trial is registered with the Pan African Clinical 
Trial Registry, number PACTR201306000550192.
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author, APB, 
EB, SG, MHN, and SM had full access to all the data in 
the study. All authors had ﬁnal responsibility for the 
decision to submit for publication.
Results
Between March, 2014, and January, 2016, 218 277 eligible 
antenatal care visits were registered in the logbooks at the 
ten clinics participating in this trial (68 598 ﬁrst visits and 
149 679 follow-up visits). No losses or exclusions of study 
facilities occurred. Figure 1 shows the distribution of 
antenatal care visits by clinic and step. The distribution 
stratiﬁed by the ﬁrst visit and follow-up visits is shown in 
the appendix. The sample size was larger for step 1 because 
this step comprised a 3-month period (baseline data 
collection), compared with a 2-month period for all sub-
sequent steps. Furthermore, clinic 10 was the largest and 
spent most of the trial in the control group; as a con-
sequence, the control period has a higher number of 
antenatal care visits than the intervention period (ﬁgure 1; 
table 1).
Women’s characteristics and antenatal care visit 
characteristics did not change over time. The distribution 
of the ﬁrst and follow-up antenatal care visits, participants’ 
ages, and gestational ages were similar between the 
control and intervention periods (table 1).
Deployment of the intervention was delayed by 1 month 
in the ﬁrst antenatal care clinic, which resulted in 
a 3-month baseline period. There were no other delays in 
rollout of the intervention. All ten clinics received the 
intervention as described in the protocol, with only 
minor deviations. The tracking sheet was simpliﬁed to 
only monitor stock levels of the kits rather than the 
various products inside them. The training session at the 
launch of the intervention in each clinic lasted 1 day 
rather than 3 days as originally planned because 1 day 
was deemed suﬃcient. During the intervention period, 
two clinics had a single 3-day period with no kits. There 
were a few isolated issues with expiry of HIV and syphilis 
tests; these issues were short lasting and were overcome 
by the health facility providing routine supplies while 
awaiting arrival of new kits.
Table 2 shows the intervention eﬀect sizes for each 
outcome. Clinically and statistically signiﬁcant improve-
ments in all three primary outcomes were observed. 
5519 (14·6%) of 37 826 women were screened for anaemia 
(the ﬁrst primary outcome) in the control period, 
compared with 30 057 (97·7%) of 30 772 women in the 
intervention period (adjusted OR 832·40; 99% CI 
666·81–1039·11; p<0·0001; table 2). 3739 (9·9%) of 
37 826 women were screened for proteinuria (the second 
primary outcome) in the control period, compared with 
29 874 (97·1%) of 30 772 women in the intervention 
period (adjusted OR 1875·18; 99% CI 1447·56–2429·11; 
p<0·0001; table 2). 17 926 (51·4%) of 34 842 women 
received mebendazole for treatment of parasitic worms 
(the third primary outcome) in the control period, 
compared with 24 960 (88·2%) of 28 294 women in the 
intervention period (adjusted OR 1·88; 99% CI 1·70–2·09; 
p<0·0001; table 2). 
Clinically and statistically signiﬁcant improvements 
were also observed in four of the six secondary outcomes 
evaluated in the ﬁrst antenatal care visits (table 2). 
A small improvement was observed in HIV screening 
and treatment but this result was not clinically signiﬁcant. 
The overall pattern of improvement was less striking in 
follow-up visits, although a statistically and clinically 
signiﬁcant increase in practice coverage was observed in 
four of the six secondary outcomes evaluated in follow-up 
visits (appendix). The intervention was also found to 
have a statistically signiﬁcant eﬀect on the composite 
outcome score (adjusted mean diﬀerence 1·72; 99% CI 
1·70–1·74; p<0·0001; appendix).
Practice delivery rates at the ﬁrst antenatal care visits 
are stratiﬁed by facility and step in ﬁgure 2. These 
secondary analyses show that practice delivery increased 
immediately after the introduction of the intervention 
(ie, in the same step the intervention was introduced), 
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Figure 1: Trial diagram showing number of antenatal care visits by antenatal care clinics and steps
Control period 
(n=122 884)
Intervention 
period (n=95 393)
First visit 37 826 (30·8%) 30 772 (32·3%)
Fourth visit 11 319 (9·2%) 8635 (9·0%)
Other follow-up visits 73 739 (60·0%) 55 986 (58·7%)
First antenatal care visit
Women screened 37 826 30 772
Age, years 24·0 (6·1) 24·1 (6·2)
Gestational age, weeks 22·9 (6·7) 22·4 (6·7)
Follow-up antenatal care visits
Women screened 85 058 64 621
Age, years 23·9 (6·0) 24·0 (6·0)
Gestational age, weeks 30·4 (6·5) 29·6 (6·5)
Data are n (%) or mean (SD).
Table 1: Population characteristics, by study period
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Control period* Intervention period* Mixed-model adjusted odds ratio 
of intervention effect (99% CI)†
p value ICC‡
Primary outcomes
Screening for anaemia 5519/37 826 (14·6%) 30 057/30 772 (97·7%) 832·40 (666·81–1039·11) <0·0001 0·588
Screening for proteinuria 3739/37 826 (9·9%) 29 874/30 772 (97·1%) 1875·18 (1447·56–2429·11) <0·0001 0·351
Treatment for worms (mebendazole) 17 926/34 842 (51·4%) 24 960/28 294 (88·2%) 1·88 (1·70–2·09) <0·0001 0·291
Secondary outcomes
Screening for high blood pressure 24 654/37 826 (65·2%) 30 487/30 772 (99·1%) 609·29 (466·69–795·46) <0·0001 0·584
Preventive treatment for malaria 12 725/19 844 (64·1%) 14 373/15 350 (93·6%) 3·68 (3·17–4·28) <0·0001 0·119
Screening for HIV 33 756/35 284 (95·7%) 27 573/28 430 (97·0%) 1·04 (0·84–1·27) 0·662 0·020
Treatment for HIV 2396/2678 (89·5%) 1622/1797 (90·3%) 1·61 (0·98–2·65) 0·013 0·088
Screening for syphilis 24 833/37 826 (65·7%) 29 385/30 772 (95·5%) 23·50 (20·56–26·86) <0·0001 0·083
Treatment for syphilis 672/1106 (60·8%) 696/807 (86·2%) 2·49 (1·38–4·51) 0·0001 0·024
Data are n/N (%), unless otherwise indicated. *Denominators vary according to the population eligible for each outcome as described in the appendix. †Mixed-model odds 
ratios account for the clustering of patients within clinics and adjust for time trends. Under the stepped-wedge design, the adjusted odds ratios are calculated with the use 
of all data points in the intervention period versus the control period and therefore represent the average odds of exposure to the intervention. ‡Intracluster correlation 
coefficient (ICC) during the control period. 
Table 2: Effect of the intervention during first antenatal care visits for primary and secondary outcomes
A Screening for anaemia (n=68 598) B Screening for proteinuria (n=68 598) C Treatment for worms (n=63 136)
D Screening for high blood pressure (n=68 598) E Treatment for malaria (n=35 194) F Screening for HIV (n=63 714)
G Treatment for HIV (n=4475) H Screening for syphilis (n=68 598) I Treatment for syphilis (n=1913)*
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8
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5
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1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11
Steps (2-month periods) Steps (2-month periods) Steps (2-month periods)
 0 97 100 100 100 100 100 99 99 98 98
 0 0 97 99 100 94 100 100 97 100 100
 100 100 100 100 100 100 97 100 99 100 100
 16 15 22 17 99 97 98 100 100 100 100
 54 94 100 98 95 99 100 99 100 97 100
 0 0 1 0 0 1 66 100 100 100 100
 2 1 1 1 11 9 1 90 99 95 99
 1 0 0 0 4 0 0 3 90 99 99
 16 57 66 73 54 51 22 1 44 98 99
 0 0 0 1 0 1 2 5 2 3 88
 47 100 100 100 95 99 100 99 100 98 100
 0 2 96 100 100 100 97 100 93 100 100
 100 100 100 100 100 100 100 100 100 100 100
 100 100 50 100 99 100 100 100 100 100 100
 90 45 64 64 45 100 96 100 100 100 100
 100 100 100 100 100 100 100 100 100 100 100
 82 100 98 74 100 100 93 100 99 100 100
 96 95 87 100 99 100 100 100 100 100 100
 55 99 100 100 60 57 72 68 94 100 100
 54 34 6 27 5 14 39 14 39 37 95
 83 50 80 83 78 100 100 80 100 80 33
 86 89 92 80 91 95 93 88 84 97 93
 86 80 33 80 100 100 86 100 100 100 80
 66 61 50 79 93 89 80 76 84 76 43
 99 98 97 97 99 100 97 99 97 97 96
 95 91 97 96 100 100 97 91 100 97 97
 95 97 100 100 100 98 97 97 94 96 100
 85 93 82 90 94 92 91 88 90 63 69
 95 98 98 100 98 97 100 96 100 94 98
 91 86 79 76 72 76 80 78 88 90 95
 0 99 87 100 100 100 100 100 100 100 100
 0 1 98 99 99 91 93 100 100 98 100
 100 100 99 100 100 100 97 100 100 100 100
 0 1 1 2 100 97 99 99 100 100 100
 71 83 100 95 91 100 100 97 100 100 100
 0 0 0 0 0 0 67 100 100 100 100
 1 0 1 0 0 1 0 91 100 99 99
 1 0 0 0 4 0 0 3 83 89 100
 15 56 42 4 0 0 1 1 7 98 99
 0 0 0 1 0 1 3 2 1 3 88
 50 95 94 98 94 97 95 99 96 98 96
 64 59 81 95 93 94 93 94 93 97 99
 85 85 94 92 91 94 96 95 99 99 99
 88 75 95 95 96 93 97 95 94 94 96
 14 26 61 69 56 73 82 85 92 92 94
 19 22 57 80 66 95 86 88 85 76 94
 54 62 79 63 88 89 96 96 98 98 97
 37 30 46 55 51 63 55 44 86 92 95
 41 74 65 67 26 91 93 94 97 94 91
 71 0 57 78 89 91 90 95 49 89 91
 55 94 98 100 98 96 97 100 100 93 97
 26 66 97 98 91 99 100 96 92 91 95
 78 95 97 50 96 74 92 97 98 86 100
 59 90 98 94 99 99 96 96 100 98 100
 69 27 58 98 80 100 99 92 99 100 100
 2 24 92 84 95 99 98 97 98 99 99
 9 71 91 99 90 98 66 99 97 99 99
 48 59 75 100 63 30 32 63 99 100 100
 28 63 98 99 99 71 99 95 57 98 96
 37 85 87 90 86 93 75 62 5 24 69
 53 90 94 98 98 97 98 99 99 98 97
 53 81 91 96 88 98 97 98 93 96 92
 69 84 90 96 84 75 77 82 82 83 77
 0 4 18 6 80 67 69 69 67 65 73
 74 77 97 91 88 97 96 96 95 92 93
 74 69 89 85 85 92 91 81 90 81 88
 3 57 78 61 78 83 97 92 95 94 90
 0 1 15 20 33 48 31 41 74 81 77
 21 53 98 92 97 99 95 97 98 97 98
 1 0 30 67 43 66 67 75 75 69 69
 91 92 96 98 95 99 99 99 98 96 99
 84 89 98 94 70 94 94 99 99 99 99
 89 97 99 95 91 97 96 99 99 100 98
 97 99 98 97 99 99 98 98 99 99 99
 99 100 100 99 95 99 99 99 99 99 99
 93 96 100 98 99 100 97 99 98 98 98
 97 100 97 99 97 99 98 100 98 98 98
 98 96 88 99 99 99 100 100 98 99 99
 98 98 97 99 98 99 100 99 100 98 100
 93 95 91 90 96 90 94 96 95 94 95
 0 97 84 90 100 94 98 100 97 100 97
 75 42 100 100 100 100 80 67 100 50 100
 40 0 25 50 40 100 100 100 100 50 75
 0 37 100 95 94 84 100 75 100 95 100
 21 0 0 94 93 100 100 91 100 100 95
  100 60 56 30 50 50 67 86 80 89
 0 50 50 100 75 33 50 0 100 0 100
 71 77 72 70 49 23 72 38 87 40 65
 38 54 79 60 75 83 80 100 100 86 80
 0 7 61 64 73 75 86 82 60 84 54
Figure 2: Outcome rates, by step and health facility; first antenatal care visits
Each cell contains the proportion of women who received each specific antenatal care practice in the corresponding antenatal care clinics and steps. For each of the nine panels in this figure, the ten clinics 
are represented in the y-axis while the steps of the trial are represented in the x-axis. *When the denominator to compute the cell rate is 0, cells are coloured in white.
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that during the intervention period almost no hetero-
geneity was observed between clinics, and that once the 
rates increased these changes were sustained over time 
(ﬁgure 2). These patterns were particularly evident for 
screening for proteinuria and anaemia (ﬁgure 2). The 
same patterns were observed for follow-up visits, which 
are presented in the appendix.
Discussion
The results of this stepped-wedge cluster-randomised 
controlled trial show that implementation of a supply 
chain strategy based on the provision of pre-packed 
supply kits at the point of care can generate major and 
long lasting improvements in practice delivery and thus 
in quality of antenatal care. Importantly, through 
integration of all essential antenatal care practices, the 
kits created the necessary conditions for a woman-centred 
approach, resulting in improvements in antenatal care 
across practices (all >80% coverage for the whole inter-
vention period). Furthermore, when looking at the eﬀect 
of the intervention in each clinic and over time, we found 
a uniform eﬀect across clinics, which was immediate and 
sustained throughout the entire intervention period.
Our simple intervention addressed several limitations 
of the health system in Mozambique. Packaging of all 
required supplies and timely delivery of these kits at the 
clinics addressed weaknesses in the procurement and 
supply systems.11 With the kits, screening for proteinuria 
and haemoglobin switched from laboratory testing to 
rapid testing, which enabled nurses to screen, diagnose, 
and treat women in a single antenatal care session, thus 
optimising the scarce contact between these women 
and the health-care system and ensuring that these 
women access the full range of recommended inter-
ventions. The shortage of human resources for antenatal 
care results in overburdened and frustrated nurses who 
are unable to deliver all recommended practices.12,16 The 
trial kits streamlined the antenatal care processes, 
achieving increased eﬃciency without increasing the 
size of the workforce.
Vertical approaches to health care, focusing on a single 
health condition, have been criticised because they can 
force busy health-care providers to deﬂect attention from 
other critical activities, which could result in deterioration 
of the overall quality of care.16–18 Baseline data from this 
trial are consistent with this view. Vertical, well-resourced 
HIV programmes are deeply established in Mozambique; 
we saw that screening and treatment for HIV were 
two practices with very high baseline coverage, at 90% or 
more, and therefore little room for improvement as 
reﬂected in the non-signiﬁcant increase, whereas 
screening for high blood pressure, proteinuria, and 
anaemia was much less common (table 2). The public 
health and practical implications of this ﬁnding are 
important, particularly in a setting where haemorrhage 
and hypertensive disorders of pregnancy are leading 
direct causes of maternal mortality.19
The supply of pre-packed kits—targeted at women, 
health-care providers, or facilities—has been proposed 
as a simple, low-cost intervention with the potential 
to address challenges routinely encountered in 
low-resource settings that prevent patients from 
receiving appropriate care.20–23 However, in maternal 
health, almost all evidence on supply kits derives from 
observational studies and has focused mainly on clean 
childbirth and reducing the incidence of infection and 
its complications, particularly in settings where women 
give birth at home.20,21 To our knowledge, this is the ﬁrst 
trial assessing supply kits targeted at health facilities as 
an intervention to improve coverage of routine 
evidence-based practices for maternal care.24
In this trial, the combination of a robust design, large 
sample size, and large eﬀect size provides a strong level 
of evidence to support the eﬀectiveness of the 
intervention, since bias or random error are unlikely to 
explain these ﬁndings. Other strengths of the study 
include the stepped-wedge design, which allowed delivery 
of the intervention in all clusters, avoiding some of the 
logistic and political challenges typically faced by 
researchers.25 We randomised the order in which facilities 
received the intervention and adjusted for potential 
secular trends. We also validated the source data by doing 
surveys with women leaving antenatal care and doing an 
audit. Contamination was deemed unlikely because it 
would imply the improbable transfer of kits between 
clinics, which were dispersed across the country. 
Additionally, the kits’ stocks were monitored.
This was a pragmatic trial designed from the ground 
up to inform policy makers. The close partnership 
between the Ministry of Health and WHO, and the 
ownership and full engagement of the Ministry of 
Health, catalysed this implementation research, embed-
ded in a real-world setting and driven by the needs and 
priorities of the country. Consequently, a relevant and 
practical intervention was designed on the basis of 
the formative research. The study population included 
all women attending antenatal care visits, with no 
exclusion criteria. The intervention was implemented 
by the available nurses under routine care conditions 
and regardless of any event occurring in the clinics 
during the trial period. We used the government 
antenatal care registration logbook as our source of 
data and thus the trial did not place additional burden 
on the health-care providers. To our knowledge, this is 
the ﬁrst trial to evaluate an intervention with these 
characteristics.
For all parties involved in the study, scaling up and 
sustainability were important considerations. Subsequent 
to the trial, the study partners, including the Ministry of 
Health, have been engaged in an assessment of the cost-
eﬀectiveness and implementation options for scaling up 
the use of antenatal care supply kits in Mozambique. 
This information will inform how antenatal care supply 
kits could be incorporated into the supply chain in 
Articles
e64 www.thelancet.com/lancetgh   Vol 6  January 2018
Mozambique, including whether the use of other (private) 
supply solutions would be feasible and cost-eﬀective.
Our study has some limitations. The stepped-wedge 
design can be vulnerable to secular trends if outcomes 
are already improving. However, the large sample size 
and large number of steps in this trial allowed us to 
estimate and adjust for time trends.15 The eﬀect might 
also be explained by diﬀerences in reporting during the 
intervention period. To avoid this problem, we isolated 
the data collection procedures from those relating to 
implementation of the interventions as much as was 
feasible and implemented strict data management 
procedures that included several data audits.
Although rapid tests for HIV and syphilis were being 
used in antenatal care before the intervention, the kits 
introduced two additional rapid tests for proteinuria and 
anaemia—the conditions for which the most substantial 
increase in screening was observed. The availability of 
rapid tests for these conditions is likely to have an eﬀect 
independently of the provision of kits.26 Unfortunately, 
however, in evaluations of complex interventions de-
livered as a package, disentangling the individual eﬀect of 
each component is not possible.
We could not report on all the initially prespeciﬁed 
secondary outcomes because of limitations in the data 
collection instrument from the Ministry of Health. Iron 
and folic acid supplementation and tetanus toxoid 
administration had to be excluded because the infor-
mation to compute these outcomes was not recorded in 
the logbook. Lastly, we did not collect data on ﬁnal 
maternal and newborn outcomes, so the overall eﬀect of 
the antenatal care practices on mortality or morbidity 
cannot be assessed. However, we only included evidence-
based practices for which the beneﬁts have already been 
clearly established.
The health-system and resource challenges under-
pinning the design of our intervention are undoubtedly 
not unique to the facilities participating in this trial or to 
Mozambique.11,12 This study provides crucial information 
to policy makers in countries with similar supply chain 
deﬁciencies but its relevance goes well beyond this 
obvious target. We believe that this simple intervention 
could be easily adapted beyond low-resource settings and 
beyond the area of maternal health. The simplicity and the 
nature of the intervention make it likely to be acceptable 
and adaptable across many countries and settings. 
However, context-speciﬁc kits need to be designed. What 
to include, where to produce and store the kits, and how to 
distribute these kits to facilities will vary across countries 
and settings and requires careful analysis to avoid the very 
same challenges that these kits aim to address.
In conclusion, although the evidence-based practices 
for improving maternal and newborn health are well 
known, approaches to eﬀectively and sustainably scale 
up these interventions are urgently needed, particularly 
in low-resource settings. The results of this study show 
that a simple intervention focused on the provision, at 
point of care, of supplies for evidence-based practices 
packaged in kits resulted in a vast improvement in 
quality of antenatal care when compared with the routine 
national system for procurement and distribution of 
supplies. The pragmatic nature of this trial, embedded in 
routine care conditions, makes these ﬁndings particularly 
valuable for policy makers in low-resource settings.
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